Strong Or Moderate Cyp3a Inducers has 14 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 10 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Lonafarnib, Neratinib, Finerenone. Patients taking Strong Or Moderate Cyp3a Inducers should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 14
- Contraindicated
- 2
- Major
- 10
- Moderate
- 2
Contraindicated (2)
- Strong Or Moderate Cyp3a Inducers + Lonafarnib— Concomitant use is contraindicated. Decreases lonafarnib Cmax and AUC, which may reduce efficacy.
- Strong Or Moderate Cyp3a Inducers + Neratinib— Concomitant use reduces neratinib Cmax and AUC, reducing NERLYNX activity. Avoid concomitant use.
Major (10)
- Strong Or Moderate Cyp3a Inducers + Finerenone— Decreases finerenone exposure which may reduce efficacy of finerenone; avoid concomitant use.
- Strong Or Moderate Cyp3a Inducers + Nerandomilast— Moderate or strong CYP3A inducers decrease exposure of nerandomilast, which may decrease the efficacy of JASCAYD. Concom…
- Strong Or Moderate Cyp3a Inducers + Omaveloxolone— Concomitant use results in clinically significant decreased exposure of omaveloxolone, which may reduce the effectivenes…
- Strong Or Moderate Cyp3a Inducers + Pimavanserin— Reduces pimavanserin exposure. Avoid concomitant use.
- Strong Or Moderate Cyp3a Inducers + Pimavanserin Tartrate— Reduces pimavanserin exposure; concomitant use should be avoided.
- Strong Or Moderate Cyp3a Inducers + Quizartinib— Concomitant use decreases quizartinib systemic exposure, which may reduce VANFLYTA efficacy. Concomitant use should be a…
- Strong Or Moderate Cyp3a Inducers + Revumenib— Concomitant use should be avoided as it may decrease revumenib systemic exposure and increase M1 metabolite exposure, re…
- Strong Or Moderate Cyp3a Inducers + Vanzacaftor, Tezacaftor, And Deutivacaftor— Concomitant use is not recommended. CYP3A inducers decrease vanzacaftor, tezacaftor, and deutivacaftor exposure, which m…
- Strong Or Moderate Cyp3a Inducers + Vonoprazan Fumarate— Strong or moderate CYP3A inducers may decrease exposure of vonoprazan and clarithromycin, reducing effectiveness of VOQU…
- Strong Or Moderate Cyp3a Inducers + Zavegepant— Concomitant administration may result in decrease in zavegepant exposure. Avoid concomitant administration.
Moderate (2)
- Strong Or Moderate Cyp3a Inducers + Deuruxolitinib Phosphate— Concomitant use decreases deuruxolitinib exposure, which may reduce LEQSELVI efficacy. Avoid concomitant use.
- Strong Or Moderate Cyp3a Inducers + Lenacapavir Sodium— May significantly decrease plasma concentrations of lenacapavir, reducing effectiveness of YEZTUGO. Dosage modifications…